Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/59055
PREVALENCE OF GENOTYPIC RESISTANCE MUTATIONS IN PATIENTS WITH CHRONIC HEPATITIS B (HBV) TREATED WITH ENTECAVIR AND TENOFOVIR IN TWO REFERENCE CENTERS IN THE NORTH AND NORTHEAST OF BRAZIL
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia e Biologia Molecular. Salvador, BA, Brasil.
Universidade Federal da Bahia. Salvador, BA, Brasil.
Universidade Federal da Bahia. Salvador, BA, Brasil.
Universidade Federal da Bahia. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia e Biologia Molecular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia e Biologia Molecular. Salvador, BA, Brasil.
Universidade Federal da Bahia. Salvador, BA, Brasil.
Universidade Federal da Bahia. Salvador, BA, Brasil.
Universidade Federal da Bahia. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia e Biologia Molecular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia e Biologia Molecular. Salvador, BA, Brasil.
Abstract
Mutations of genotypic resistance to nucleotide analogues Entecavirand Tenofovirhave been described in patients undergoing treatment and virgins for hepatitis B virus. The present study demonstrated in a sample of 263 patients with chronic HBV from the North and Northeast of Brazil, a mutation rate of resistance to nucleotide analogues of 3.8% (10). Of the 10 patients who had genotypic resistance mutations, only 1 had no genotypic resistance mutation for the first line treatment for hepatitis B, entecavir and tenofovir.Due to the emergence of vaccine escape mutations and resistance mutations to antiviral treatment, and the severity of liver disease caused by HBV, screening for genetic mutations is important due to the impact on therapeutic management.
Share